Distinct signaling profiles of β1 and β2 adrenergic receptor ligands toward adenylyl cyclase and mitogen-activated protein kinase reveals the pluridimensionality of efficacy

Molecular Pharmacology

Volumn 70, Issue 5, 2006, Pages 1575-1584

  Galandrin, Ségolène ^a   Bouvier, Michel ^a  

^a UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ATENOLOL; BETA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; BISOPROLOL; BUCINDOLOL; CARVEDILOL; ISOPRENALINE; LABETALOL; METOPROLOL; MITOGEN ACTIVATED PROTEIN KINASE; PROPRANOLOL DERIVATIVE;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG POTENCY; HEART FAILURE; HUMAN; HUMAN CELL; HYPERTENSION; PRIORITY JOURNAL;

ADENYLATE CYCLASE; CYCLIC AMP; HUMANS; LIGANDS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; PHOSPHORYLATION; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; SIGNAL TRANSDUCTION;

EID: 33751162165     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.106.026716     Document Type: Article

References (33)

1. Audet N, Paquin-Gobeil M, Landry-Paquet O, Schiller PW, and Pineyro G (2005) Internalization and Src activity regulate the time course of ERK activation by delta opioid receptor ligands. J Biol Chem 280:7808-7816.
2. Azzi M, Charest PG, Angers S, Rousseau G, Kohout T, Bouvier M, and Pineyro G (2003) Beta-arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors. Proc Natl Acad Sci USA 100:11406-11411.
3. Baker JG, Hall IP, and Hill SJ (2003) Agonist and inverse agonist actions of β-blockers at the human β2-adrenoceptor provide evidence for agonist-directed signaling. Mol Pharmacol 64:1357-1369.
4. Berg KA, Maayani S, Goldfarb J, Scaramellini C, Leff P, and Clarke WP (1998) Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus. Mol Pharmacol 54:94-104.
5. Bond RA (1997) Do recent operational studies indicate that a single state model is no longer applicable to G protein-coupled receptors? Ann N Y Acad Sci 812:92-97.
6. Gay EA, Urban JD, Nichols DE, Oxford GS, and Mailman RB (2004) Functional selectivity of D2 receptor ligands in a Chinese hamster ovary HD2L cell line: evidence for induction of ligand-specific receptor states. Mol Pharmacol 66:97-105.
7. Gbahou F, Rouleau A, Morisset S, Parmentier R, Crochet S, Lin JS, Ligneau X, Tardivel-Lacombe J, Stark H, Schunack W, Ganellin CR, Schwartz JC, and Arrang JM (2003) Protean agonism at histamine H3 receptors in vitro and in vivo. Proc Natl Acad Sci USA 100:11086-11091.
8. Ghanouni P, Gryczynski Z, Steenhuis JJ, Lee TW, Farrens DL, Lakowicz JR, and Kobilka BK (2001) Functionally different agonists induce distinct conformations in the G protein coupling domain of the beta 2 adrenergic receptor. J Biol Chem 276:24433-24436.
9. Hall DA, Beresford IJ, Browning C, and Giles H (1999) Signalling by CXC-chemokine receptors 1 and 2 expressed in CHO cells: a comparison of calcium mobilization, inhibition of adenylyl cyclase and stimulation of GTPgammaS binding induced by IL-8 and GROalpha. Br J Pharmacol 126:810-818.
10. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, and Klotz KN (2004) Comparative pharmacology of human beta-adrenergic receptor subtypes- characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg's Arch Pharmacol 369:151-159.
11. Kenakin T (1995) Agonist-receptor efficacy. II. Agonist trafficking of receptor signals. Trends Pharmacol Sci 16:232-238.
12. Kenakin T (2001) Inverse, protean, and ligand-selective agonism: matters of receptor conformation. FASEB J 15:598-611.
13. Kenakin T (2002) Drug efficacy at G protein-coupled receptors. Annu Rev Pharmacol Toxicol 42:349-379.
14. Kenakin T (2003) Ligand-selective receptor conformations revisited: the promise and the problem. Trends Pharmacol Sci 24:346-354.
15. Kenakin T (2004) Principles: receptor theory in pharmacology. Trends Pharmacol Sci 25:186-192.
16. Krueger KM, Witte DG, Ireland-Denny L, Miller TR, Baranowski JL, Buckner S, Milicic I, Esbenshade TA, and Hancock AA (2005) G protein-dependent pharmacology of histamine H3 receptor ligands: evidence for heterogeneous active state receptor conformations. J Pharmacol Exp Ther 314:271-281.
17. Kurrasch-Orbaugh DM, Watts VJ, Barker EL, and Nichols DE (2003) Serotonin 5-hydroxytryptamine 2A receptor-coupled phospholipase C and phospholipase A2 signaling pathways have different receptor reserves. J Pharmacol Exp Ther 304:229-237.
18. Lavoie C, Mercier JF, Salahpour A, Umapathy D, Breit A, Villeneuve LR, Zhu WZ, Xiao RP, Lakatta EG, Bouvier M, and Hebert TE (2002) β1/β2-Adrenergic receptor heterodimerization regulates β2-adrenergic receptor internalization and ERK signaling efficacy. J Biol Chem 277:35402-35410.
19. McLaughlin JN, Shen L, Holinstat M, Brooks JD, Dibenedetto E, and Hamm HE (2005) Functional selectivity of G protein signaling by agonist peptides and thrombin for the protease-activated receptor-1. J Biol Chem 280:25048-25059.
20. Milligan G (2003) Constitutive activity and inverse agonists of G protein-coupled receptors: a current perspective. Mol Pharmacol 64:1271-1276.
21. Moniri NH, Covington-Strachan D, and Booth RG (2004) Ligand-directed functional heterogeneity of histamine H1 receptors: novel dual-function ligands selectively activate and block H1-mediated phospholipase C and adenylyl cyclase signaling. J Pharmacol Exp Ther 311:274-281.
22. Pauwels PJ, Gommeren W, Van Lommen G, Janssen PA, and Leysen JE (1988) The receptor binding profile of the new antihypertensive agent nebivolol and its stereoisomers compared with various β-adrenergic blockers. Mol Pharmacol 34:843-851.
23. Ponicke K, Groner F, Heinroth-Hoffmann I, and Brodde OE (2006) Agonist-specific activation of the beta2-adrenoceptor/Gs-protein and beta2-adrenoceptor/Gi-protein pathway in adult rat ventricular cardiomyocytes. Br J Pharmacol 147:714-719.
24. Ponicke K, Heinroth-Hoffmann I, and Brodde OE (2002) Differential effects of bucindolol and carvedilol on noradenaline-induced hypertrophic response in ventricular cardiomyocytes of adult rats. J Pharmacol Exp Ther 301:71-76.
25. Reeves PJ, Thurmond RL, and Khorana HG (1996) Structure and function in rhodopsin: high level expression of a synthetic bovine opsin gene and its mutants in stable mammalian cell lines. Proc Natl Acad Sci USA 93:11487-11492.
26. Spengler D, Waeber C, Pantaloni C, Holsboer F, Bockaert J, Seeburg PH, and Journot L (1993) Differential signal transduction by five splice variants of the PACAP receptor. Nature (Lond) 365:170-175.
27. Strange PG (2002) Mechanisms of inverse agonism at G-protein-coupled receptors. Trends Pharmacol Sci 23:89-95.
28. Swaminath G, Deupi X, Lee TW, Zhu W, Thian FS, Kobilka TS, and Kobilka B (2005) Probing the β2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists. J Biol Chem 280:22165-22171.
29. Urban JD, Clarke WP, von Zastrow M, Nichols DE, Kobilka BK, Weinstein H, Javitch JA, Roth BL, Christopoulos A, Sexton P, Miller K, Spedding M, and Mailman RB (2006) Functional selectivity and classical concepts of quantitative pharmacology. J Pharmacol Exp Ther, in press.
30. Vauquelin G and Van LI (2005) G protein-coupled receptors: a count of 1001 conformations. Fundam Clin Pharmacol 19:45-56.
31. Watson C, Chen G, Irving P, Way J, Chen WJ, and Kenakin T (2000) The use of stimulus-biased assay systems to detect agonist-specific receptor active states: implications for the trafficking of receptor stimulus by agonists. Mol Pharmacol 58:1230-1238.
32. Werry TD, Gregory KJ, Sexton PM, and Christopoulos A (2005) Characterization of serotonin 5-HT2C receptor signaling to extracellular signal-regulated kinases 1 and 2. J Neurochem 93:1603-1615.
33. Xiao RP, Zhang SJ, Chakir K, Avdonin P, Zhu W, Bond RA, Balke CW, Lakatta EG, and Cheng H (2003) Enhanced G(i) signaling selectively negates beta2-adrenergic receptor (AR)-but not beta1-AR-mediated positive inotropic effect in myocytes from failing rat hearts. Circulation 108:1633-1639.